Edivoxetine

Edivoxetine

Chemical structure of Edivoxetine

Edivoxetine is a pharmaceutical compound that was under development as a potential treatment for major depressive disorder (MDD). It is classified as a selective norepinephrine reuptake inhibitor (NRI), which means it primarily affects the neurotransmitter norepinephrine in the brain. Edivoxetine was being developed by the pharmaceutical company Eli Lilly and Company.

Pharmacology

Edivoxetine functions by inhibiting the reuptake of norepinephrine, thereby increasing its availability in the synaptic cleft. This mechanism is thought to contribute to its potential antidepressant effects. Unlike some other antidepressants, edivoxetine does not significantly affect the reuptake of serotonin or dopamine, making it a more selective agent.

Development and Clinical Trials

Ball-and-stick model of Edivoxetine

Edivoxetine was evaluated in several clinical trials to assess its efficacy and safety in treating major depressive disorder. However, the results from these trials were not sufficiently positive to support its continued development for this indication. The trials indicated that while edivoxetine was generally well-tolerated, its efficacy in alleviating symptoms of depression was not significantly better than placebo.

Potential Uses

Although its development for major depressive disorder was discontinued, edivoxetine's pharmacological profile suggests it could be explored for other conditions where norepinephrine modulation might be beneficial. These could include attention deficit hyperactivity disorder (ADHD) or certain types of anxiety disorders. However, as of the latest updates, no further development has been reported.

Chemical Properties

Edivoxetine is a small molecule with a specific chemical structure that allows it to selectively inhibit norepinephrine reuptake. The chemical structure of edivoxetine is depicted in the accompanying images, which illustrate both the structural formula and a ball-and-stick model.

Related Pages

• Major depressive disorder
• Selective norepinephrine reuptake inhibitor
• Eli Lilly and Company
• Norepinephrine